Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

• DOI: 10.1007/s12015-020-10092-9
• Publication Date: 2021-01-06T23:08:32Z
• Authors: Jia Feng; Haichan Xu; Andrew Cinquina; Zehua Wu; Qi Chen; Ping Zhang; Xingen Wang; Huiming Shan; Lei Xu; Qian Zhang; Lihua Sun; Wenli Zhang; Kevin G. Pinz; Masayuki Wada; Xun Jiang; William M Hanes; Yupo Ma; Hongyu Zhang
• Keywords: CD5; Lymphoblastic lymphoma

Abstract While treatment for B-cell malignancies has been revolutionized through the advent of CAR immunotherapy, similar strategies T-cell have limited. Additionally, leukemias and lymphomas can commonly metastasize to CNS, where outcomes are poor options associated with severe side effects. Consequently, development safer more effective alternatives targeting malignant T cells that invaded CNS remains clinically important. CD5 previously shown effectively target various cancers in preclinical studies. As IL-15 strengthens anti-tumor response, we modified secrete an IL-15/IL-15sushi complex. In a Phase I clinical trial, these CD5-IL15/IL15sushi were tested safety efficacy patient refractory T-LBL infiltration. able rapidly ablate lymphoblasts within few weeks, resulting remission patient’s lymphoma. Despite presence on normal cells, only experienced brief, transient aplasia. These results suggest may be safe useful particularly beneficial patients involvement. Graphical